VCVericel VCEL · NASDAQ
$54.62 +5.48% (+$2.84)
- Market cap
- $2.80B
- Enterprise value
- $2.75B
- P/E
- 84.0x
- Forward P/E
- 101.2x
- PEG
- 2.9x
- P/S
- 8.6x
- P/FCF
- 61.0x
- EV/EBITDA
- 57.1x
- ROIC
- 5.5%
- Gross margin
- 74.5%
- Net margin
- 10.3%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -0.9x
- Beta
- 1.06
- Free float
- 98.8%
About the company
Vericel Corporation is a biotechnology company that specializes in the development and commercialization of advanced therapies for tissue regeneration. The company primarily focuses on treating severe wounds, burns, and orthopedic conditions, offering autologous cell therapies that use a patient’s own cells to support healing and regeneration. Its key products include Epicel, a therapy for burn treatment, and Carticel, a cell therapy for cartilage repair.
Sector
Healthcare
Industry
Biotechnology
CEO
Dominick C. Colangelo
Employees
398
Headquarters
Burlington
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Revenue grew by 19% a year over the last 3 years.
- What speaks for it: Analysts expect revenue to grow by 22% this fiscal year.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 USD of revenue, 14 USD is left as free cash.
- What to watch: It earns only 5.5 USD a year on every 100 USD of invested capital.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $133.5M against $91.1M.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number